Heterocyclic compound
A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.
1. A compound
selected from the group consisting of
1-(1-((2-cyclopropyl-4′-fluoro-5-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-2-oxo-1,2-dihydropyridine-4-carboxylic acid,
1-(1-((6-cyclopropyl-2,4′-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, and
1-(1-((6-cyclopropyl-2,4′-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid, or a salt thereof.
2. 1-(1-((2-Cyclopropyl-4′-fluoro-5-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-2-oxo-1,2-dihydropyridin-4-carboxylic acid or a salt thereof.
3. 1-(1-((6-Cyclopropyl-2,4′-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-ethyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid or a salt thereof.
4. 1-(1-((6-Cyclopropyl-2,4′-difluoro-3-isopropoxybiphenyl-4-yl)methyl)piperidin-4-yl)-3-methyl-2-oxo-1,2-dihydropyridine-4-carboxylic acid or a salt thereof.
5. A medicament comprising the compound of claim 1 or a salt thereof.
6. The medicament of claim 5 , which is a somatostatin receptor 5 antagonist.
7. The medicament of claim 5 , which is an agent for the treatment of diabetes mellitus.
8. A method for treating diabetes mellitus in a mammal, comprising administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.
9. A method for antagonizing somatostatin receptor subtype 5 in a mammal, comprising administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.
10. The compound according to claim 1 or a salt thereof for the treatment of diabetes mellitus.